The DNAJC19 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the MES-OV human ovarian carcinoma epithelial cell line, designed to eliminate DNAJC19 gene function. This product provides a loss-of-function model for studying the mitochondrial inner membrane co-chaperone DNAJC19, which participates in mitochondrial protein import and cardiolipin remodeling. The polyclonal format ensures a heterogeneous knockout population suitable for diverse experimental applications without the need for single-cell cloning.
The parental MES-OV cell line originates from a human ovarian adenocarcinoma and represents a mesonephric-like adenocarcinoma model, a distinct subtype of epithelial ovarian cancer. These cells are widely employed in cancer research to explore tumorigenic mechanisms, metabolic reprogramming, and therapeutic responses. Their epithelial origin and malignant characteristics make them an appropriate host for knockout studies investigating the role of mitochondrial chaperones in ovarian cancer pathophysiology.
DNAJC19 functions as a critical co-chaperone at the mitochondrial inner membrane, where it interacts with the TIMM44?CmtHSP70 motor complex to mediate import of nuclear-encoded mitochondrial proteins. This activity is essential for the assembly of respiratory chain complexes I, III, and IV, and for cardiolipin remodeling through interactions with prohibitins PHB and PHB2. DNAJC19 is transcriptionally regulated upstream by PPARGC1A (PGC-1??) and NRF1 in response to mitochondrial stress signals, and it coordinates downstream with mitochondrial respiratory complexes and cardiolipin synthases. Loss of DNAJC19 disrupts these processes, leading to impaired oxidative phosphorylation and compromised mitochondrial integrity.
In the MES-OV ovarian cancer background, DNAJC19 knockout allows researchers to dissect how mitochondrial chaperone dysfunction influences cancer cell metabolism, proliferation, and survival. Given the reliance of many tumors on mitochondrial oxidative metabolism and cardiolipin homeostasis, this model enables examination of metabolic vulnerabilities under nutrient stress, glucose deprivation, or hypoxic conditions, and can reveal sensitization to chemotherapeutics such as platinum-based agents. Furthermore, it provides a system to investigate mitochondrial quality control pathways and their intersection with oncogenic signaling, supporting the identification of novel therapeutic targets.
Typical applications include functional genomics studies using Seahorse metabolic flux analysis to assess oxidative phosphorylation and glycolysis, mitochondrial membrane potential assays, and immunofluorescence imaging of mitochondrial morphology. Co-immunoprecipitation experiments can probe interactions with DNAJC19 partners such as TIMM44, PHB2, and mtHSP70, while RT-qPCR and western blotting permit profiling of mitochondrial gene expression and protein levels. This knockout model is also valuable for drug target validation in mitochondrial disease contexts like dilated cardiomyopathy with ataxia (DCMA) and for screening small molecules that modulate mitochondrial function. For further information, please contact Ascent Research.
